(ACLX) Arcellx - Overview
Stock: DdCAR, Anitocabtagene Autoleucel, ACLX-001, ACLX-002, ACLX-003
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 47.7% |
| Relative Tail Risk | -5.92% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.17 |
| Alpha | -14.58 |
| Character TTM | |
|---|---|
| Beta | 0.841 |
| Beta Downside | 0.804 |
| Drawdowns 3y | |
|---|---|
| Max DD | 50.44% |
| CAGR/Max DD | 0.62 |
Description: ACLX Arcellx January 11, 2026
Arcellx, Inc. (NASDAQ: ACLX) is a U.S.-based biotech focused on next-generation immunotherapies, primarily its proprietary ddCAR platform. Its lead candidate, anitocabtagene autoleucel, is in a Phase 2 trial for relapsed or refractory multiple myeloma (RR-MM), while a pipeline of early-stage products targets BCMA (ACLX-001), CD123 (ACLX-002), and solid-tumor antigens (ARC-SparX, ACLX-003). The company operates under a co-development and co-commercialization agreement with Kite Pharma for anitocabtagene autoleucel.
Beyond the DD-CAR assets, Arcellx maintains a cash runway of roughly $120 million as of its latest 10-Q, giving it ~12-month liquidity at current burn rates (~$10 M / quarter). The broader CAR-T market is projected to expand at a CAGR of 30 % through 2030, driven by increasing approvals and payer acceptance, which underpins the upside potential for ddCAR-based therapies.
Investors should note that Arcellx’s current market capitalization hovers around $350 million, implying a price-to-cash ratio of ≈3×, but the valuation is highly sensitive to Phase 2 read-outs and any competitive breakthroughs in BCMA-targeted CAR-T (e.g., from Janssen or Legend). For a deeper, data-driven valuation of ACLX, the ValueRay platform offers a granular, scenario-based model worth reviewing.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -217.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.31 > 0.02 and ΔFCF/TA -31.14 > 1.0 |
| NWC/Revenue: 985.3% < 20% (prev 289.0%; Δ 696.3% < -1%) |
| CFO/TA -0.30 > 3% & CFO -198.1m > Net Income -217.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (56.6m) vs 12m ago 5.14% < -2% |
| Gross Margin: -2.25% > 18% (prev 0.97%; Δ -322.4% > 0.5%) |
| Asset Turnover: 5.05% > 50% (prev 20.37%; Δ -15.32% > 0%) |
| Interest Coverage Ratio: -11.4k > 6 (EBITDA TTM -209.5m / Interest Expense TTM 19.0k) |
Altman Z'' -5.08
| A: 0.54 (Total Current Assets 472.1m - Total Current Liabilities 118.4m) / Total Assets 655.9m |
| B: -1.02 (Retained Earnings -667.6m / Total Assets 655.9m) |
| C: -0.30 (EBIT TTM -216.3m / Avg Total Assets 710.4m) |
| D: -3.10 (Book Value of Equity -666.9m / Total Liabilities 215.1m) |
| Altman-Z'' Score: -5.08 = D |
What is the price of ACLX shares?
Over the past week, the price has changed by -0.41%, over one month by +9.62%, over three months by -22.87% and over the past year by -0.31%.
Is ACLX a buy, sell or hold?
- StrongBuy: 12
- Buy: 6
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ACLX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 112.4 | 65.1% |
| Analysts Target Price | 112.4 | 65.1% |
| ValueRay Target Price | 74.2 | 9% |
ACLX Fundamental Data Overview February 02, 2026
P/B = 8.973
Revenue TTM = 35.9m USD
EBIT TTM = -216.3m USD
EBITDA TTM = -209.5m USD
Long Term Debt = 51.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 7.47m USD (from shortTermDebt, last quarter)
Debt = 51.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -27.2m USD (from netDebt column, last quarter)
Enterprise Value = 3.54b USD (3.95b + Debt 51.8m - CCE 461.4m)
Interest Coverage Ratio = -11.4k (Ebit TTM -216.3m / Interest Expense TTM 19.0k)
EV/FCF = -17.60x (Enterprise Value 3.54b / FCF TTM -201.2m)
FCF Yield = -5.68% (FCF TTM -201.2m / Enterprise Value 3.54b)
FCF Margin = -560.4% (FCF TTM -201.2m / Revenue TTM 35.9m)
Net Margin = -607.0% (Net Income TTM -217.9m / Revenue TTM 35.9m)
Gross Margin = -2.25% ((Revenue TTM 35.9m - Cost of Revenue TTM 36.7m) / Revenue TTM)
Gross Margin QoQ = none% (prev 78.58%)
Tobins Q-Ratio = 5.40 (Enterprise Value 3.54b / Total Assets 655.9m)
Interest Expense / Debt = 0.04% (Interest Expense 19.0k / Debt 51.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -170.9m (EBIT -216.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.99 (Total Current Assets 472.1m / Total Current Liabilities 118.4m)
Debt / Equity = 0.12 (Debt 51.8m / totalStockholderEquity, last quarter 440.8m)
Debt / EBITDA = 0.13 (negative EBITDA) (Net Debt -27.2m / EBITDA -209.5m)
Debt / FCF = 0.14 (negative FCF - burning cash) (Net Debt -27.2m / FCF TTM -201.2m)
Total Stockholder Equity = 426.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -30.67% (Net Income -217.9m / Total Assets 655.9m)
RoE = -51.13% (Net Income TTM -217.9m / Total Stockholder Equity 426.2m)
RoCE = -45.26% (EBIT -216.3m / Capital Employed (Equity 426.2m + L.T.Debt 51.8m))
RoIC = -40.10% (negative operating profit) (NOPAT -170.9m / Invested Capital 426.2m)
WACC = 8.90% (E(3.95b)/V(4.00b) * Re(9.02%) + D(51.8m)/V(4.00b) * Rd(0.04%) * (1-Tc(0.21)))
Discount Rate = 9.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.04%
Fair Price DCF = unknown (Cash Flow -201.2m)
EPS Correlation: 31.64 | EPS CAGR: 39.06% | SUE: 2.36 | # QB: 1
Revenue Correlation: 64.71 | Revenue CAGR: 56.88% | SUE: -0.51 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.10 | Chg30d=-0.004 | Revisions Net=+1 | Analysts=9
EPS next Year (2026-12-31): EPS=-3.50 | Chg30d=-0.224 | Revisions Net=+1 | Growth EPS=+12.9% | Growth Revenue=+262.8%